- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients
-
Taki S, Tamai H, Ida Y, Shingaki N, Kawashima , Shimizu R, Moribata K, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2404722
- Gut Liver.
- 2018 Jan;12(1):86-93.
- doi: 10.5009/gnl17048
BACKGROUND/AIMS: Although daclatasvir with asunaprevir was approved in Japan for interferon ineligible or intolerant patients, patients aged ≥75 years were excluded in the phase III trial. The present study aimed... -
- CITED
-
- Close
- SHARE
-
- Close
- Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus
-
Tamai H, Ida Y, Kawashima , Shingaki N, Shimizu R, Moribata K, Nasu T, Maekita T, Iguchi M, Kato J, Nakao T, Kitano M
- KMID: 2412236
- Gut Liver.
- 2017 Jul;11(4):551-558.
- doi: 10.5009/gnl16525
BACKGROUND/AIMS: The present study aimed to evaluate the safety and efficacy of simeprevir-based triple therapy with reduced doses of pegylated interferon (PEG-IFN) and ribavirin for interferon (IFN) ineligible patients, such... -
- CITED
-
- Close
- SHARE
-
- Close
- Low-Dose Pegylated Interferon α-2b Plus Ribavirin for Elderly and/or Cirrhotic Patients with Genotype 2 Hepatitis C Virus
-
Tamai H, Shingaki N, Mori Y, Moribata K, Kawashima , Maeda Y, Niwa T, Deguchi H, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 2412052
- Gut Liver.
- 2016 Jul;10(4):617-623.
- doi: 10.5009/gnl15193
BACKGROUND/AIMS: This study aimed to predict sustained viral response (SVR) to low-dose pegylated interferon (PEG-IFN) plus ribavirin of elderly and/or cirrhotic patients with genotype 2 hepatitis C virus (HCV) using... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediction of a Null Response to Pegylated Interferon alpha-2b Plus Ribavirin in Patients with High Viral Load Genotype 1b Hepatitis C
-
Wada Y, Tamai H, Kawashima , Shingaki N, Mori Y, Kawaguchi , Moribata K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M
- KMID: 1792366
- Gut Liver.
- 2014 Jul;8(4):421-427.
BACKGROUND/AIMS: The present study aimed to clarify whether virological response within 2 weeks after therapy initiation can predict a null response to pegylated interferon alpha-2b plus ribavirin therapy in patients... -
- CITED
-
- Close
- SHARE
-
- Close
